Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

CEF regimen × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

CYP3A Phenotyping 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 2810 Cisplatin 2802 Carboplatin 2597 Radiotherapy 2491 Paclitaxel 2384 Gemcitabine 2234 pembrolizumab 2082 Docetaxel 1956 Bevacizumab 1938 Fluorouracil 1635 Capecitabine 1619 Oxaliplatin 1525 Dexamethasone 1400 Nivolumab 1372 Doxorubicin 1324 Rituximab 1316 Magnetic Resonance Spectroscopy 1211 Etoposide 1187 Irinotecan 1103 Leucovorin 1081 Drug Therapy 1053 Cytarabine 1002 Pemetrexed 930 fludarabine 930 Specimen Handling 870 Vincristine 836 Prednisone 833 Lenalidomide 832 Cetuximab 823 Trastuzumab 822

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00593697 2015-03-06

SOLD

Finnish Breast Cancer Group

Phase 3 Completed

Breast Neoplasms

NCT01110291 2010-04-27

Docetaxel

University of Turku

CYP3A Phenotyping

Data powered by HemOnc (CC BY 4.0) Colophon ⚡